Munar Pharma Stock

Munar Pharma P/E 2025

Munar Pharma P/E

36.05

Ticker

MUN.WA

ISIN

PLSITE000013

WKN

A1J15E

As of Jul 31, 2025, Munar Pharma's P/E ratio was 36.05, a -191.89% change from the -39.23 P/E ratio recorded in the previous year.

The Munar Pharma P/E history

Munar Pharma Aktienanalyse

What does Munar Pharma do?

Munar Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Munar Pharma's P/E Ratio

The Price to Earnings (P/E) Ratio of Munar Pharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Munar Pharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Munar Pharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Munar Pharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Munar Pharma stock

What is the price-to-earnings ratio of Munar Pharma?

The price-earnings ratio of Munar Pharma is currently 36.05.

How has the price-earnings ratio of Munar Pharma changed compared to last year?

The price-to-earnings ratio of Munar Pharma has increased by -191.89% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Munar Pharma high compared to other companies?

Yes, the price-to-earnings ratio of Munar Pharma is high compared to other companies.

How does an increase in the price-earnings ratio of Munar Pharma affect the company?

An increase in the price-earnings ratio of Munar Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Munar Pharma affect the company?

A decrease in the price-earnings ratio of Munar Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Munar Pharma?

Some factors that influence the price-earnings ratio of Munar Pharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Munar Pharma pay?

Over the past 12 months, Munar Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Munar Pharma is expected to pay a dividend of 0 PLN.

What is the dividend yield of Munar Pharma?

The current dividend yield of Munar Pharma is .

When does Munar Pharma pay dividends?

Munar Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Munar Pharma?

Munar Pharma paid dividends every year for the past 0 years.

What is the dividend of Munar Pharma?

For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.

In which sector is Munar Pharma located?

Munar Pharma is assigned to the 'Communication' sector.

Wann musste ich die Aktien von Munar Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Munar Pharma from 7/31/2025 amounting to 0 PLN, you needed to have the stock in your portfolio before the ex-date on 7/31/2025.

When did Munar Pharma pay the last dividend?

The last dividend was paid out on 7/31/2025.

What was the dividend of Munar Pharma in the year 2024?

In the year 2024, Munar Pharma distributed 0 PLN as dividends.

In which currency does Munar Pharma pay out the dividend?

The dividends of Munar Pharma are distributed in PLN.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Munar Pharma

Our stock analysis for Munar Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Munar Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.